China
Africa
Explore chapters and articles related to this topic
Common/useful drugs
Published in Jonathan P Rogers, Cheryl CY Leung, Timothy RJ Nicholson, Pocket Prescriber Psychiatry, 2019
Jonathan P Rogers, Cheryl CY Leung, Timothy RJ Nicholson
Interactions:☠↑risk of severe toxic reaction with serotonergics, dopaminergics and noradrenergics: SSRIs, SNRIs, NARIs, TCAs (and related drugs), other MAOIs (inc for Parkinson's disease), carbamazepine, linezolid, triptans, pethidine, tramadol.☠Do not start isocarboxazid until these drugs have been stopped and they have cleared: 5 wk for fluoxetine, 3 wk for clomipramine/imipramine, at least 7–14 days for other drugs.Wait 2 wk after stopping isocarboxazid before starting any of these medicines.
Psychotropic Drugs
Published in Diana Riley, Perinatal Mental Health, 2018
Two authors84,85 assert that therapeutic doses of tranylcypromine (Parnate) are secreted in breast milk in doses too small to affect the child. Another100 states that no ill effects have been noted in the infants of mothers taking isocarboxazid (Marplan), but goes on to say that animal studies on nialamide (Niamid) have shown that the maturation of young is affected, and that there is a high mortality rate in the offspring. In view of the potential for interaction of this group of drugs with other medication or dietary factors, it would be unwise to continue breast-feeding while taking this group of drugs.
MAO Inhibitors: Predicting Response/Maximizing Efficacy
Published in Mark S. Gold, R. Bruce Lydiard, John S. Carman, Advances in Psychopharmacology: Predicting and Improving Treatment Response, 2018
Giller et al.13 found that those patients who responded best to isocarboxazid had mild to moderate severity of depression and measurable anxiety and somatic complaints. Similarly, Raft et al.14 found a marked response to phenelzine in a pain clinic population who also met criteria for major depression. This too is consistent with the association of somatic complaints and MAOI responsivity.
Marine natural products with monoamine oxidase (MAO) inhibitory activity
Published in Pharmaceutical Biology, 2020
Ahreum Hong, Le Cam Tu, Inho Yang, Kyung-Min Lim, Sang-Jip Nam
There are several classes of MAOI drugs on the market based on reversibility and selectivity (Shulman et al. 2013; Entzeroth and Ratty 2017). Reversibility means the way of the inhibitor binding into the enzyme whether covalently or non-covalently. Selectivity is a preference for one of the MAO subtypes. Non-selective and irreversible MAOI such as isocarboxazid, phenelzine and tranylcypromine were approved to treat depression in the US (Shulman et al. 2013). Selective MAO-A inhibitors with reversibility such as brofaromin and moclobemide were employed to treat social anxiety disorder (Entzeroth and Ratty 2017). However, the results were contradictory that these were not approved in the US. Irreversible MAO-B inhibitors, selegiline and rasagiline, were used to treat the symptoms of Parkinson's disease (Dezsi and Vecsei 2017). At present, the development of reversible, specific and safe MAOIs is required.
MAO inhibitors and their wider applications: a patent review
Published in Expert Opinion on Therapeutic Patents, 2018
Simone Carradori, Daniela Secci, Jacques P. Petzer
Based on the various biological roles, and future and existing clinical applications of MAO inhibitors, much interest have been invested in the development of inhibitors of these enzymes. In this respect, both reversible and irreversible MAO inhibitors are used in the clinic. MAO-A inhibitors that have been used for the treatment of depression include phenelzine, isocarboxazid, tranylcypromine, and iproniazid (Figure 3) [36].